These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 11786980)

  • 21. Management of hepatitis C virus genotype 4.
    Abdo AA; Lee SS
    J Gastroenterol Hepatol; 2004 Nov; 19(11):1233-9. PubMed ID: 15482528
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Hepatitis C and drug use: epidemiology, screening, natural history and treatment].
    Lucidarme D
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B112-20. PubMed ID: 12180278
    [No Abstract]   [Full Text] [Related]  

  • 23. Hepatitis C virus virology and new treatment targets.
    Meier V; Ramadori G
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):329-50. PubMed ID: 19344246
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II clinical trial of VX-497 for HCV infection begins.
    AIDS Patient Care STDS; 1998 Dec; 12(12):944. PubMed ID: 11362074
    [No Abstract]   [Full Text] [Related]  

  • 25. [Treatment of recurrent hepatitis C].
    Berenguer M
    Gastroenterol Hepatol; 2000 Feb; 23 Suppl 1():63-7. PubMed ID: 11968347
    [No Abstract]   [Full Text] [Related]  

  • 26. [Hepatitis C is curable. Even slightly elevated liver enzymes need further examination].
    Niederau C
    MMW Fortschr Med; 2008 Mar; 150(13):26. PubMed ID: 18522352
    [No Abstract]   [Full Text] [Related]  

  • 27. Management strategies using pharmacogenomics in patients with severe HCV-1b infection: a decision analysis.
    Moriguchi H; Uemura T; Kobayashi M; Chung RT; Sato C
    Hepatology; 2002 Jul; 36(1):177-85. PubMed ID: 12085363
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Hepatitis C in childhood--natural history and therapy].
    Nagata I; Murakami J; Okamoto M; Iitsuka T; Kanzaki S; Shiraki K
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):634-9. PubMed ID: 15359875
    [No Abstract]   [Full Text] [Related]  

  • 29. Hepatitis C and the 'cure'.
    Cooksley WG
    Aust Fam Physician; 1998 Dec; 27(12):1086. PubMed ID: 9919728
    [No Abstract]   [Full Text] [Related]  

  • 30. Treating HCV with ribavirin analogues and ribavirin-like molecules.
    Gish RG
    J Antimicrob Chemother; 2006 Jan; 57(1):8-13. PubMed ID: 16293677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Infection fighters. Hepatitis C and HIV.
    TreatmentUpdate; 2005; 17(1):7. PubMed ID: 17225318
    [No Abstract]   [Full Text] [Related]  

  • 32. Existing and future therapeutic options for hepatitis C virus infection.
    Bretner M
    Acta Biochim Pol; 2005; 52(1):57-70. PubMed ID: 15827606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Hepatitis C: therapeutic perspectives].
    Trépo C
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B297-302. PubMed ID: 12180304
    [No Abstract]   [Full Text] [Related]  

  • 34. Current and future concepts in hepatitis C therapy.
    Pawlotsky JM
    Semin Liver Dis; 2005 Feb; 25(1):72-83. PubMed ID: 15731999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of patients with chronic hepatitis C virus infection and normal transaminases].
    Serfaty L
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B202-5. PubMed ID: 12180289
    [No Abstract]   [Full Text] [Related]  

  • 36. [Current and future applications of viral clearance kinetics in the treatment of hepatitis C].
    Buti M
    Gastroenterol Hepatol; 2004 Feb; 27 Suppl 1():24-9. PubMed ID: 15195531
    [No Abstract]   [Full Text] [Related]  

  • 37. Another ten stories in antiviral drug discovery (part C): "Old" and "new" antivirals, strategies, and perspectives.
    De Clercq E
    Med Res Rev; 2009 Jul; 29(4):611-45. PubMed ID: 19260077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Should treatment of hepatitis C in HIV-seropositive and HIV-seronegative patients with hemophilia include induction doses of interferon?
    McGovern B; Bica I
    Clin Infect Dis; 2003 Aug; 37(3):463-4; author reply 464-5. PubMed ID: 12884180
    [No Abstract]   [Full Text] [Related]  

  • 39. Focus on hepatitis. Increased RBV dose for better HCV treatment response.
    Bernard EJ
    IAPAC Mon; 2006 Jan; 12(1):18. PubMed ID: 17249131
    [No Abstract]   [Full Text] [Related]  

  • 40. Implications of finding synergic in vitro drug-drug interactions between interferon-alpha and ribavirin for the treatment of hepatitis C virus.
    Buckwold VE
    J Antimicrob Chemother; 2004 Mar; 53(3):413-4. PubMed ID: 14963071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.